Introduction
The number of patients with chronic kidney disease (CKD) is increasing. Unfortunately, the survival of CKD patients remains poor. Among other factors, cardiovascular disease (CVD) is the leading cause of death in CKD patients. Both traditional and non-traditional factors play a role for increased cardiovascular mortality. Among traditional risk factors, diabetes, hypertension and dyslipidemia are the leading causes. Anaemia, inflammation, oxidative stress, disorders of calcium phosphorus metabolism, arterial stiffness and malnutrition can be stated as non-traditional risk factors [1] [2] [3] . Thus, it is of no question that CKD patients can be considered as high-risk patients. In previous reports such as Adult Treatment Panel (ATP) III, there was no specific interest regarding the dyslipidemia in CKD patients. Thus in response to the recommendations of the National Kidney Foundation (NKF) Task Force on CVD, the NKF Kidney Disease Outcomes Quality Initiative (K/DOQI) convened a work group to develop guidelines for the management of dyslipidemias, one of the risk factors for CVD in CKD. This critical review gives brief information about these guidelines first and the interpretation of these guidelines based on the recently conducted randomized prospective studies thereafter.
Discussion
The author has referenced some of its own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies. 
Adult

Treating dyslipidemias according to K/DOQI
The K/DOQI suggests that: · For adults with stage 5 CKD and fasting triglycerides ≥ 500 (10-25 g/day) and plant sterols (2 g/day) as therapeutic options enhance LDL lowering), weight management and increased physical activity are strongly recommended. ATP III reports have identified LDL-C as the primary target of cholesterol-lowering therapy. Lipoprotein levels must be obtained after 9-12 hours of fasting.
According to the ATP III algorithm, people are categorized into three risk categories: (1) established coronary heart disease (CHD) and CHD risk equivalents, (2) multiple (2+) risk factors and (3) zero to one (0-1) risk factor.
CHD risk equivalents include non-coronary forms of clinical atherosclerotic disease and diabetes. Major risk factors other than LDL-C include cigarette smoking, hypertension (BP >140/90 mmHg or on antihypertensive medication), low high-density lipoprotein cholesterol (HDL-C) (<40 mg/dl) and a family history of premature CHD (CHD in male first-degree relative <55 years; CHD in female first-degree relative <65 years; age: men>45 years, women >55 years). Besides, HDL-C >60 mg/dl counts as a 'negative' risk factor, and its presence removes one risk factor from the total count. All people with CHD or CHD risk equivalents should be accepted as high risk.
However, in ATP III guidelines, no specific comments were made on patients with CKD, and CKD patients were not managed differently from other patients. The ATP III only notes that nephrotic syndrome is a cause of secondary dyslipidemia and suggests consideration be given to the use of cholesterol-lowering drugs if hyperlipidemia persists despite specific treatment for kidney disease. The ATP III also notes that various dyslipidemias have been reported in patients with kidney failure. However, the ATP III suggests that a cautious approach be taken, since these patients are prone to drug side effects, for example, they are at increased risk of myopathy 636 served as a control. The primary end point was a composite of death from cardiac causes, non-fatal myocardial infarction and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined. After a median of a 4-year follow-up, 469 patients (37%) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk 0.92; 95% CI 0.77-1.10; P = 0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95% CI 1.05-3.93; P = 0.04). The authors concluded that atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction and stroke in patients with diabetes receiving haemodialysis 20 . However, post hoc analysis of the 4D study demonstrated that atorvastatin significantly reduced the rate of adverse outcomes in patients with a baseline LDL-C level in the highest quartile but not in any of the other three quartiles 21 . Another randomized, double-blind prospective trial with rosuvastatin in ESRD was recently published. The AURORA trial (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events) involved 2,776 patients, 50-80 years of age, who were undergoing maintenance haemodialysis. Patients were randomly assigned patients to receive rosuvastatin, 10 mg daily, or placebo. The combined primary end point was death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke. Secondary end points included death from all causes and individual cardiac and vascular events. During a median follow-up period of 3.8 years, rosuvastatin had no effect on individual components of the primary end point. There was also no significant relative risk of all-cause mortality by 19%, the relative risk of cardiovascular mortality by 20% and the relative risk of non-fatal cardiovascular events by 25% 13 . Thus it was concluded that statin therapy is effective in reducing CVD especially in the early stages of CKD [14] [15] [16] [17] . Based on the data, a recent review suggested more specifically that it is better for CKD patients with stage 1-3 to use statins, whereas the beneficial role of statins beyond stage 3 CKD is less clear 6 . Apart from statins, there are also studies investigating the effects of fibrates in CKD patients. In a randomized study, Tonelli et al. investigated the effects of gemfibrozil in secondary prevention of cardiovascular events. After a median follow-up of 5.3 years, gemfibrozil treatment significantly reduced the risk of the composite outcome of fatal CHD, non-fatal myocardial infarction and stroke compared with placebo 18 . In another study, Davis et al. investigated the effect of fenofibrate therapy on renal functions in 9,795 type 2 diabetic patients. Estimated GFR had fallen less from baseline on fenofibrate than on placebo (P < 0.001). Fenofibrate reduced urine albumin concentrations and hence albumin/creatinine ratio by 24% versus 11% (P < 0.001; mean difference 14% [95% CI 9-18]; P < 0.001), with 14% less progression and 18% more albuminuria regression (P < 0.001) than in participants on placebo. End-stage renal event frequency was similar (n = 21 vs. 26, P = 0.48). The authors concluded that fenofibrate reduced albuminuria and slowed eGFR loss over 5 years, and fenofibrate may delay albuminuria and GFR impairment in type 2 diabetes patients 19 .
Studies of dyslipidemia treatment in CKD patients on dialysis
In a 4D study, Wanner et al. recruited 1,255 diabetic patients with endstage renal disease (ESRD). About 619 patients were in the intervention group (atorvastatin 20mg/dl) and reductase inhibitor) on cardiovascular outcomes in patients with CKD who are not undergoing dialysis therapy. The pravastatin pooling project showed that the relative risk reduction in major cardiovascular events observed among patients with an estimated glomerular filtration rate (GFR) of ≥30 ml/min/1.73 m 2 and <60 ml/min/1.73 m 2 was similar to that observed in patients with a GFR ≥60 ml/min/1.73 m 2 (23% and 22%, respectively) 6 . A meta-analysis of randomized, placebo-controlled trials that included >6,500 patients with CKD demonstrated that statins significantly reduced both serum lipid concentrations and the incidence of cardiovascular end points, without evidence of increased adverse effects 7 . However, since the studies were primarily designed to assess cardiovascular outcomes in patients with cardiac disease or at high risk of developing cardiac disease and lacked predefined kidney function outcomes, consequently, the renal findings derived from post hoc analyses might be misleading 6 . Thus to diminish these drawbacks, various trials randomly assigned participants to statin therapy versus control [8] [9] [10] [11] . As a cumulative result of these studies, it was concluded that statins did not decrease all-cause mortality or stroke in participants with diabetes and CKD 12 . However, statin therapy increased regression of microalbuminuria to normoalbuminuria, but did not attenuate the decrease in estimated GFR (eGFR) in patients with baseline albuminuria 9 . However, the aforementioned studies were conducted on diabetic CKD patients. To be more comprehensive, Navaneethan et al. evaluated the benefits of statins in patients with non-dialysis-dependent CKD with or without cardiovascular comorbidities, including randomized controlled trials and comparing statins with placebo. The meta-analysis involved more than 18,500 patients, and showed that statins reduced the 
Conclusion
While preparing the dyslipidemia guidelines for CKD patients, the K/ DOQI working group anticipated from the beginning that all guidelines should be updated whenever new, pertinent information becomes available. To anticipate when these guidelines may need to be updated, the Work Group discussed ongoing clinical trials in the general population and in patients with CKD, as those results may be pertinent to some recommendations. They also have reasonable doubt as to whether trial results from the general population are applicable to all patients with CKD. The major trials (4D, AURORA, SHARP) were not completed when these guidelines were prepared. Thus from these findings, a new guideline incorporating the data of a recent research is necessary. It is of no question that a effect on all-cause mortality. Interestingly, an increased incidence of fatal haemorrhagic stroke was noted in patients with diabetes mellitus in the rosuvastatin group, compared with patients with diabetes mellitus in the placebo group. The authors concluded that the initiation of treatment with rosuvastatin lowered the LDL-C level in patients undergoing haemodialysis but had no significant effect on the composite primary end point of death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke 22 . Last, it is worth mentioning the study of Heart and Renal Protection (SHARP) trial 23 . This randomized double-blind trial included 9,270 patients with both CKD and ESRD on haemodialysis and peritoneal dialysis (3,023 on dialysis and 6,247 not on dialysis) with no known history of myocardial infarction or coronary revascularization. Patients were randomly assigned to simvastatin 20 mg plus ezetimibe 10 mg daily (4,650 patients) versus matching placebo (4,620 patients). The key prespecified outcome was the first major atherosclerotic event (non-fatal myocardial infarction or coronary death, non-haemorrhagic stroke or any arterial revascularization procedure). All analyses were by intention to treat. After a 4.9-year follow-up, there was a 17% proportional reduction in major atherosclerotic events in simvastatin plus ezetimibe vs. 
